Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Clinical role
Parallel triage and notification tool that passively prioritizes suspected occlusion cases without removing cases from the worklist or altering original DICOM images
Images and patients
CT/CTA · Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Key limitation
Keep in mind: Pediatric patients were not tested; notifications and preview images are not diagnostic; the device does not detect, localize, characterize, measure, or diagnose vascular disease, and the clinician must review the full study
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries Input: DICOM CTA studies of adult patients covering the aorta through the popliteal arteries; the Gateway receives a PACS copy, checks metadata, de-identifies it, and sends it to the VAOT cloud for processing
Who uses it?Intended users: Hospital networks and trained medical specialists, including radiologists and appropriately trained specialists
What does the software produce?Output: PACS/RIS workstation notification and a binary prioritization flag for possible total arterial occlusion; when flagged, an axial preview from the original study is returned as a DICOM Secondary Capture for informational use only
What is its most important limitation?Key limitation: Pediatric patients were not tested; notifications and preview images are not diagnostic; the device does not detect, localize, characterize, measure, or diagnose vascular disease, and the clinician must review the full study
Clinical takeaway. Clinical role: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Evidence takeaway. Evidence from the reviewed source record: Retrospective, blinded, multicenter pivotal study used 317 US cases, 165 positive and 152 negative, distinct from training data. Ground truth was majority vote of three expert US board-certified radiologists; the sample was enriched for aortic occlusions. Sensitivity was 91.5% (95% CI 86.2%-95.3%) and specificity 90.1% (84.2%-94.4%) against an 80% performance goal. Secondary time-to-notification endpoint was less than 5 minutes, including DICOM receipt, de-identification, cloud upload, analysis, and notification return
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Parallel triage and notification tool that passively prioritizes suspected occlusion cases without removing cases from the worklist or altering original DICOM images
DICOM CTA studies of adult patients covering the aorta through the popliteal arteries; the Gateway receives a PACS copy, checks metadata, de-identifies it, and sends it to the VAOT cloud for processing
PACS/RIS workstation notification and a binary prioritization flag for possible total arterial occlusion; when flagged, an axial preview from the original study is returned as a DICOM Secondary Capture for informational use only
Pediatric patients were not tested; notifications and preview images are not diagnostic; the device does not detect, localize, characterize, measure, or diagnose vascular disease, and the clinician must review the full study
Retrospective, blinded, multicenter pivotal study used 317 US cases, 165 positive and 152 negative, distinct from training data. Ground truth was majority vote of three expert US board-certified radiologists; the sample was enriched for aortic occlusions. Sensitivity was 91.5% (95% CI 86.2%-95.3%) and specificity 90.1% (84.2%-94.4%) against an 80% performance goal. Secondary time-to-notification endpoint was less than 5 minutes, including DICOM receipt, de-identification, cloud upload, analysis, and notification return
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Retrospective, blinded, multicenter pivotal study used 317 US cases, 165 positive and 152 negative, distinct from training data. Ground truth was majority vote of three expert US board-certified radiologists; the sample was enriched for aortic occlusions. Sensitivity was 91.5% (95% CI 86.2%-95.3%) and specificity 90.1% (84.2%-94.4%) against an 80% performance goal. Secondary time-to-notification endpoint was less than 5 minutes, including DICOM receipt, de-identification, cloud upload, analysis, and notification return
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Vascular Assist Occlusion Triage (VAOT) v1.0 regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K260729
Samplen=317
IndependenceIndependence not established
K260729
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K260729. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM CTA studies of adult patients covering the aorta through the popliteal arteries; the Gateway receives a PACS copy, checks metadata, de-identifies it, and sends it to the VAOT cloud for processing
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Gateway acts as a PACS listener, receives DICOM from PACS, transmits the de-identified study to the VAOT cloud, re-associates a returned preview, embeds it in DICOM Secondary Capture, and routes it to a DICOM destination such as PACS; exact local interfaces and versions are not established
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: PACS/RIS workstation notification and a binary prioritization flag for possible total arterial occlusion; when flagged, an axial preview from the original study is returned as a DICOM Secondary Capture for informational use only
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: PACS/RIS workstation notification and a binary prioritization flag for possible total arterial occlusion; when flagged, an axial preview from the original study is returned as a DICOM Secondary Capture for informational use only
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Gateway acts as a PACS listener, receives DICOM from PACS, transmits the de-identified study to the VAOT cloud, re-associates a returned preview, embeds it in DICOM Secondary Capture, and routes it to a DICOM destination such as PACS; exact local interfaces and versions are not established
ACR AI Central provides an exact-submission model card for Vascular Assist Occlusion Triage (VAOT) (v1.0); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K260729 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Assist hospital networks and appropriately trained physician specialists by flagging suspected acute cervical-spine fractures on cervical-spine CT for triage and prioritization; it is not designed to detect vertebral compression fractures.
Modality
CT/CTA
Anatomy
Cervical spine; acute cervical-spine fractures including non-displaced lines and displaced fragments
Authorized purpose: BriefCase is a radiological computer-aided triage and notification software indicated for use in the analysis of CT exams with contrast (CTA and CT with contrast) that include the chest in adults or transitional adolescents aged 18 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communicating suspected positive cases of aortic dissection (AD) pathology. Briefcase uses an artificial intelligence algorithm to analyze images and highlight cases with detected findings on a Stand-Alone Performance application in parallel to the ongoing standard of care image interpretation. The user is presented with notifications for cases with suspected findings. Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device. The results of BriefCase are intended to be used in conjunction with other patient information and based on the user's professional judgment, to assist with triage/prioritization of medical images. Notified clinicians are responsible for viewing full images per the standard of care.
Authorized purpose: BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of CTPA images in adults or transitional adolescents aged 18 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communication of suspected positive findings of Pulmonary Embolism (PE) pathologies. Briefcase uses an artificial intelligence algorithm to analyze images and highlight cases with detected findings on a Stand-Alone Performance desktop application in parallel to the ongoing standard of care image interpretation. The user is presented with notifications for cases with suspected PE findings. Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device. The results of BriefCase are intended to be used in conjunction with other patient information and based on their professional judgment, to assist with triage/prioritization of medical images. Notified clinicians are responsible for viewing full images per the standard of care.
Authorized purpose: BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of head CTA images in adults or transitional adolescents aged 18 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communication of M1 Large Vessel Occlusion (M1-LVO) pathologies. Briefcase uses an artificial intelligence algorithm to analyze images and highlight cases with detected findings on a Stand-Alone Performance desktop application in parallel to the ongoing standard of care image interpretation. The user is presented with notifications for cases with suspected findings. Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device. The results of BriefCase are intended to be used in conjunction with other patient information and based on their professional judgment, to assist with triage/prioritization of medical images. Notified clinicians are responsible for viewing full images per the standard of care.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.